Mission Statement, Vision, & Core Values (2026) of Shenzhen Kangtai Biological Products Co., Ltd.

Founded in 1992, Shenzhen Kangtai Biological Products Co., Ltd. has grown into a powerhouse in human vaccines with five major R&D and industrial bases across Shenzhen and Beijing, a product lineup that includes the world's first 60‑microgram hepatitis B vaccine and the innovative 13‑valent dual‑carrier pneumococcal conjugate vaccine, a nationwide marketing and distribution footprint covering all 31 provinces of China, and more than 70 international collaborations that together underscore how its mission-"Produce the Best Vaccines to Benefit Mankind"-and vision of becoming a world‑renowned biopharmaceutical multinational drive investments in technological innovation, resource conservation and high product quality, while core values like People‑orientation, Excellence, Honesty, Efficiency, Innovation and Cohesion shape a culture recognized by honors such as the "Cup of Safety and Health in China" and the "Worker Pioneer Honor" to meet both domestic vaccination needs and global public‑health challenges

Shenzhen Kangtai Biological Products Co., Ltd. (300601.SZ) - Intro

Established in 1992, Shenzhen Kangtai Biological Products Co., Ltd. (300601.SZ) is a leading Chinese biopharmaceutical company focused on the research, development, manufacturing and commercialization of human vaccines. Over three decades the company has scaled infrastructure, product diversity and market reach to become a major vaccine supplier in China with growing international collaboration.

• Five R&D and industrial bases located in Shenzhen and Beijing, underpinning large-scale vaccine development and GMP-compliant production capacity.
• Nationwide marketing and distribution coverage across all 31 provincial-level regions in China, supporting routine immunization and public health campaigns.
• More than 70 international partnerships spanning clinical development, technology transfer and distribution agreements, supporting global outreach.

Mission

• Protect public health through safe, effective and accessible vaccines.
• Advance vaccine science by investing in R&D, platform technologies and quality manufacturing.
• Deliver value to patients, healthcare systems and shareholders by scaling production and ensuring supply reliability.

Vision

• Be a globally trusted vaccine innovator from China - driving prevention of infectious diseases through next-generation immunization solutions.
• Expand international footprint while maintaining leadership in domestic immunization programs and outbreak preparedness.

Core Values

• Patient first - safety, efficacy and accessibility as non-negotiable priorities.
• Scientific rigor - evidence-based R&D and continuous quality improvement.
• Collaboration - open partnerships with domestic and international institutions.
• Integrity - regulatory compliance, ethical conduct and transparent reporting.
• Agility - rapid response to epidemiological needs and technological advances.

Strategic Capabilities & Product Highlights

Kangtai's product portfolio and platform strengths illustrate how mission and vision translate into tangible outputs:

• Innovative vaccines: developer of the world's first 60‑microgram hepatitis B vaccine formulation, demonstrating dose-optimization and immunogenicity focus.
• Conjugate vaccine leadership: producer of a dual-carrier 13‑valent pneumococcal polysaccharide conjugate vaccine designed to broaden serotype coverage.
• Manufacturing scale: multi-site production network enabling year-round supply for national immunization program contracts and commercial markets.

How Mission & Values Align with Business Metrics

• Quality & safety - reflected in awards and regulatory approvals across multiple product lines.
• R&D investment - concentrated in five major bases to shorten development cycles and scale clinical programs.
• Market access - nationwide distribution infrastructure enabling participation in public procurement and immunization initiatives.
• Internationalization - 70+ partnerships to support exports, joint development and technology exchange.

For investor-focused context and stakeholder analysis, see: Exploring Shenzhen Kangtai Biological Products Co., Ltd. Investor Profile: Who's Buying and Why?

Shenzhen Kangtai Biological Products Co., Ltd. (300601.SZ) - Overview

Shenzhen Kangtai Biological Products Co., Ltd. (300601.SZ) operates with a clear, enduring mission: 'Produce the Best Vaccines to Benefit Mankind.' This mission shapes strategic priorities, R&D allocation, manufacturing scale-up and global public-health engagement - guiding choices that balance commercial performance with societal impact.

Mission Statement

The company's mission commits to delivering high-quality vaccines that improve global health and community well‑being. Operationally, this translates into sustained investments in R&D, manufacturing quality systems, regulatory compliance, and global distribution capabilities.

• Mission: 'Produce the Best Vaccines to Benefit Mankind' - continuous since company founding and central to corporate governance.
• Focus areas: vaccine safety, immunogenicity, scalable manufacturing, and regulatory alignment with WHO, NMPA and other authorities.
• Strategic alignment: mission informs portfolio prioritization (preventive vaccines, seasonal/epidemic response, and novel platforms).

Vision

The vision of Shenzhen Kangtai is to be a leading global vaccine innovator and manufacturer that reliably protects populations and enables equitable access to immunization.

• Global manufacturer with integrated R&D-to-commercialization capability.
• Leadership in selected vaccine categories (inactivated, subunit, recombinant platforms) and capacity for rapid epidemic-response vaccine scale-up.
• Reputation aspiration: trusted supplier for national immunization programs and international procurement.

Core Values

• Science-driven innovation: prioritizing evidence-based development and clinical rigor.
• Quality & safety: manufacturing to recognized GMP standards and continuous quality improvement.
• Public health commitment: prioritizing accessibility and supporting immunization programs.
• Integrity & compliance: ethical conduct across trials, regulatory submissions and commercial activities.
• Collaboration: partnering with academic, clinical and global health organizations to accelerate impact.

Operational Metrics & Financial Context

Key operational and financial metrics highlight how the mission and values are translated into measurable activity and investment.

How the Mission Drives R&D and Portfolio Strategy

• R&D intensity: target of double-digit % of revenue allocated to early-stage research, clinical development and platform optimization.
• Pipeline prioritization: vaccines for high-burden infectious diseases, improved formulations for older vaccines, and scalable platforms for emergency vaccines.
• Clinical development: multiple phase II/III programs and post-marketing studies to validate safety and effectiveness in diverse populations.

Quality, Compliance, and Manufacturing Excellence

• GMP compliance across major sites with continual improvement investments (automation, analytics, supply‑chain controls).
• Quality metrics: low batch failure rates, routine regulatory inspections passed, and certified cold-chain logistics for temperature-sensitive products.
• Capacity for surge manufacturing to respond to public-health emergencies consistent with mission-driven preparedness.

Public-Health Impact & Market Position

Shenzhen Kangtai leverages its mission to secure roles in national immunization programs and international tenders, strengthening both public-health impact and commercial resilience.

• Role in immunization programs: approved supplier for multiple domestic vaccine programs and selected exports to global markets.
• Market share: leading positions in select vaccine categories domestically, with expanding international footprint.
• Stakeholder engagement: collaborations with public-health agencies, NGOs and academic centers to broaden access and validate impact.

For additional investor-focused context and ownership dynamics, see: Exploring Shenzhen Kangtai Biological Products Co., Ltd. Investor Profile: Who's Buying and Why?

Shenzhen Kangtai Biological Products Co., Ltd. (300601.SZ) - Mission Statement

• Becoming a leading and world-renowned biopharmaceutical multinational company that pursues high product quality, high corporate efficiency, technological innovation, resource conservation, and harmonious development.

• High product quality - strict GMP compliance, multi-layered quality control, and post-market surveillance to ensure vaccine and biologic safety.
• High corporate efficiency - process optimization, integrated supply-chain management, and digital transformation to shorten product development and delivery cycles.
• Technological innovation - emphasis on R&D pipelines (vaccines, therapeutic biologics, novel adjuvants) and collaborations with academic and industrial partners.
• Resource conservation - adoption of energy- and material-efficient manufacturing, waste reduction programs, and sustainable facility designs.
• Harmonious development - workforce development, community health initiatives, and compliance with international regulatory and ethical standards.

• Pipeline expansion: targeted development of next-generation vaccines and therapeutic biologics with annual milestones tied to clinical-stage progression.
• Capital allocation: sustained R&D spend, capacity investments, and selective M&A to accelerate global footprint.
• Quality & compliance: investment in advanced quality systems and international regulatory filings to access new markets.
• Sustainability initiatives: projects to reduce energy intensity per unit produced and to increase resource reuse across sites.
• Talent & culture: programs to attract biomedical scientists, regulatory experts, and manufacturing specialists to support multinational ambitions.

Shenzhen Kangtai Biological Products Co., Ltd. (300601.SZ) - Vision Statement

• People orientation - valuing employees, partners, patients and communities; fostering an inclusive, safe, and development-focused workplace.
• Excellence - setting high standards across R&D, manufacturing, quality control and customer service to ensure product reliability and regulatory compliance.
• Honesty - committing to transparency, ethical conduct, and integrity in clinical data, regulatory submissions, and stakeholder communications.
• Efficiency - optimizing processes, reducing lead times, and improving resource utilization to respond rapidly to public health demands.
• Innovation - investing in new vaccine platforms, adjuvants, and process technologies to maintain technological leadership and broaden the product pipeline.
• Cohesion - promoting teamwork, cross-functional collaboration and aligned incentives to translate strategy into execution.

• People orientation: employee-focused KPIs - training hours per employee, workplace safety incident rate, and retention metrics drive HR investments.
• Excellence & Honesty: quality metrics - batch release yield, OOS (out-of-spec) rates, and audit findings inform continuous improvement and compliance transparency.
• Efficiency: operational KPIs - throughput (doses/year), manufacturing lead-times, and cost-per-dose targets steer capacity planning.
• Innovation: R&D investment and pipeline progression - R&D spend, IND/CTA filings, and clinical-stage programs measure innovation output.
• Cohesion: cross-functional program success rates and employee engagement scores show organizational unity in delivering projects.

• People orientation and cohesion reduce turnover and preserve institutional knowledge critical for complex biologics manufacturing.
• Excellence and honesty underpin regulatory success - faster approvals, fewer enforcement actions, and stronger trust with public health authorities.
• Efficiency and innovation together lower unit costs while enabling rapid scale-up during outbreak responses.

• Board oversight and compliance functions align with the value of honesty; regular external audits and published quality metrics reinforce transparency.
• Investor communications and ESG reporting increasingly reflect Kangtai's focus on people, environment and governance consistent with its stated values.